ImmunoGen Newswire

ImmunoGen Newswire

Comprehensive Real-Time News Feed for ImmunoGen.

Results 1 - 20 of 559 in ImmunoGen

  1. Head-To-Head Contrast: ImmunoGenRead the original story w/Photo

    3 hrs ago | IntersportsWire

    ImmunoGen and Heron Therapeutics are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations. 67.6% of ImmunoGen shares are owned by institutional investors.

    Comment?

  2. ImmunoGen, Inc. (IMGN) Downgraded to Sell at ValuEngineRead the original story w/Photo

    Yesterday | Daily Political

    A number of other research firms also recently issued reports on IMGN. Cowen and Company restated a hold rating on shares of ImmunoGen in a research report on Tuesday, August 29th.

    Comment?

  3. Somewhat Favorable News Coverage Somewhat Unlikely to Affect ImmunoGen (IMGN) Stock PriceRead the original story w/Photo

    19 hrs ago | IntersportsWire

    Press coverage about ImmunoGen has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources.

    Comment?

  4. ImmunoGen, Inc. (IMGN) Stake Maintained by Massey Quick & Co. LLCRead the original story w/Photo

    21 hrs ago | IntersportsWire

    Massey Quick & Co. LLC continued to hold its position in shares of ImmunoGen, Inc. during the 2nd quarter, according to the company in its most recent 13F filing with the SEC.

    Comment?

  5. EAM Investors LLC Purchases Shares of 582,865 ImmunoGen, Inc.Read the original story w/Photo

    22 hrs ago | IntersportsWire

    EAM Investors LLC purchased a new stake in ImmunoGen, Inc. in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 582,865 shares of the biotechnology company's stock, valued at approximately $4,144,000.

    Comment?

  6. Winners Announced for 4th Annual World ADC AwardsRead the original story

    Yesterday | PR.com

    ... of September 21 at the Sheraton San Diego Marina at 7:15pm. The Awards are sponsored by Abbvie (Headline Sponsor), Immunogen (Long Standing Contribution to the Field), Ambrx (Best ADC Platform Technology) and Medimmune (Best Publication 2016). The ...

    Comment?

  7. ImmunoGen, Inc. (IMGN) Downgraded by ValuEngineRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    A number of other brokerages have also weighed in on IMGN. Zacks Investment Research lowered ImmunoGen from a "hold" rating to a "sell" rating in a research note on Monday, July 10th.

    Comment?

  8. Analyzing ImmunoGenRead the original story w/Photo

    Friday Sep 22 | AmericanBankingNews.com

    ImmunoGen and Heron Therapeutics are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends. ImmunoGen has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.

    Comment?

  9. Analysts Expect ImmunoGen, Inc. (IMGN) Will Post Quarterly Sales of $23.69 MillionRead the original story w/Photo

    Thursday Sep 21 | AmericanBankingNews.com

    Equities analysts expect that ImmunoGen, Inc. will post sales of $23.69 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for ImmunoGen's earnings.

    Comment?

  10. Antibody Drug Conjugate Market Trends, Consumption, Drivers,...Read the original story w/Photo

    Wednesday Sep 20 | SBWire

    ... Key Players for Antibody Drug Conjugate Market: - Seattle Genetics (US) - ImmunoGen, Inc.(US) - Roche Holding AG (Switzerland) - Genentech (US) - Concortis Biotherapeutics (US) - Agensys, Inc. (US) - Antikor (UK) Study Objectives of Antibody Drug ...

    Comment?

  11. ImmunoGen, Inc. (IMGN) Holdings Lifted by AxaRead the original story w/Photo

    Wednesday Sep 20 | IntersportsWire

    Axa raised its stake in shares of ImmunoGen, Inc. by 504.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 307,800 shares of the biotechnology company's stock after purchasing an additional 256,900 shares during the quarter.

    Comment?

  12. ImmunoGen (IMGN) Receives Coverage Optimism Rating of 0.21Read the original story w/Photo

    Monday Sep 18 | Daily Political

    News stories about ImmunoGen have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time.

    Comment?

  13. Antibody Drug Conjugates Market Expected to Reach $3,198 Million by 2023Read the original story w/Photo

    Monday Sep 18 | SBWire

    ... highest CAGR in 2016, in Asia-Pacific. The key companies profiled in the report include F. Hoffman-La Roche Ltd., ImmunoGen, Inc., Bayer AG, Novartis AG, Immunomedics, Inc., Agensys, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, ...

    Comment?

  14. Investment Analysts' Recent Ratings Updates for ImmunoGenRead the original story w/Photo

    Monday Sep 18 | AmericanBankingNews.com

    They now have a $10.00 price target on the stock, up previously from $8.00. 8/29/2017 - ImmunoGen had its "hold" rating reaffirmed by analysts at Cowen and Company.

    Comment?

  15. ImmunoGen, Inc. (IMGN) VP Sells $101,470.00 in StockRead the original story w/Photo

    Friday Sep 15 | AmericanBankingNews.com

    ImmunoGen, Inc. VP Craig Barrows sold 14,600 shares of the business's stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $6.95, for a total transaction of $101,470.00.

    Comment?

  16. ImmunoGen, Inc. (IMGN) VP Craig Barrows Sells 37,050 SharesRead the original story w/Photo

    Friday Sep 15 | AmericanBankingNews.com

    ImmunoGen, Inc. VP Craig Barrows sold 37,050 shares of the company's stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $6.81, for a total value of $252,310.50.

    Comment?

  17. CytomX to Present at the Cantor Fitzgerald Healthcare ConferenceRead the original story

    Wednesday Sep 13 | Customer Interaction Solutions

    ... has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter .

    Comment?

  18. ImmunoGen, Inc. (IMGN) Stock Price Down 10.6%Read the original story w/Photo

    Tuesday Sep 12 | Daily Political

    Shares of ImmunoGen, Inc. were down 10.6% during mid-day trading on Tuesday . The company traded as low as $6.71 and last traded at $6.75.

    Comment?

  19. Why Shares of ImmunoGen, Inc. Sank TodayRead the original story w/Photo

    Tuesday Sep 12 | Fox News

    The biotech exchanged $15.1 million of the $84.9 million in outstanding notes in exchange for 22,604,196 shares. If the company had waited until the notes matured, it would have been able to give the note holders 2,331,986 fewer shares, but the premium exchange rate allows ImmunoGen to avoid the interest due on the notes in the meantime.

    Comment?

  20. Tuesday Sector Laggards: Electric Utilities, Biotechnology StocksRead the original story

    Tuesday Sep 12 | MarketNewsVideo

    ... s, down on the day by about 0.8% as a group, led down by Advaxis (NASDAQ: ADXS ), trading lower by about 16.9% and Immunogen (NASDAQ: IMGN ), trading lower by about 8.3%.

    Comment?